DelMar Pharmaceuticals announces $10M registered direct offering at-the-market
DelMar Pharmaceuticals announced that it entered into securities purchase agreements with certain institutional investors in connection with a registered direct offering, priced at-the-market, of an aggregate of 8M shares of common stock and warrants to purchase an aggregate of 8M shares of common stock, at an offering price of $1.25 per share and related warrant, for an aggregate gross proceeds of $10M. The warrants have an exercise price of $1.25 per share, are immediately exercisable and have a term of exercise of five years. The offering is expected to close on or about September 22, 2017, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co., is acting as exclusive placement agent for the offering.